Dr Meenu

@bpsmv.ac.in

ASSISTANT PROFESSOR and DEPARTMENT OF PHARMACEUTICAL EDUCATION & RESEARCH
Bhagat Phool Singh Mahila Vishwavidyalaya

Dr Meenu


               Download Compact PDF  
https://researchid.co/meenu25dec88

RESEARCH, TEACHING, or OTHER INTERESTS

Pharmaceutical Science, Organic Chemistry, Analytical Chemistry, Computer Science
4

Scopus Publications

Scopus Publications

  • Role and Responsibilities of Various Stakeholders in Pharmacovigilance
    Pinki Phougat, Meenu Beniwal, Garima Kapoor, Navidha Aggarwal, Aanchal Kumari, Rashmi Sharma, Hitesh Chopra, Rohit Sharma, Mohammad Amjad Kamal
    Current Drug Safety, 2025
    : In this review paper, we have analyzed the potential and issues associated with Pharmacovigilance (PV). The analysis is divided into four sections: background, stakeholders, data sources, and medicinal chemistry. Each section discusses the current state, the future trends, and the best practices of Pharmacovigilance (PV). The main purpose, methods, results, and implications of our analysis are summarized. Background: PV is the science and practice of monitoring, evaluating, understanding, and preventing adverse drug reactions. PV was established by the World Health Organization in response to the thalidomide tragedy of 1961. The main purpose of PV is to ensure the safety and efficacy of drugs in clinical practice. Stakeholders: PV involves various stakeholders, such as patients, pharmacists, pharmaceutical companies, healthcare professionals, and regulatory authorities. Each stakeholder has a different role and responsibility in reporting, processing, analyzing, and communicating information about adverse drug reactions. Patient engagement is a key factor for enhancing PV practices. Data Sources: PV relies on data from various sources, such as clinical trials, spontaneous reports, electronic medical records, biomedical literature, and patient-reported data in online health forums. These data sources can provide valuable insights into the real-world use and safety of drugs, as well as the preferences and needs of patients. However, these data sources also pose challenges in terms of quality, validity, reliability, and accessibility. Medicinal Chemistry: Medicinal chemistry is the branch of chemistry that deals with the design, synthesis, and evaluation of new drugs and their biological effects. Medicinal chemistry can enhance PV practices by finding new therapeutic indications for existing drugs or compounds that have already been tested for safety and efficacy. Medicinal chemistry also requires careful design and evaluation of covalent inhibitors, bi-substrate inhibitors, stabilizers of protein non-effective conformations, and hydrophobic pocket modifiers to ensure their safety and efficacy. Implications: PV is a dynamic and evolving discipline that requires collaboration, regulation, education, and innovation to improve patient safety and care. This review aims to provide a comprehensive overview of the potential and issues associated with PV practices.
  • Design, synthesis, anticancer evaluation and docking studies of novel 2-(1-isonicotinoyl-3-phenyl-1H-pyrazol-4-yl)-3-phenylthiazolidin-4-one derivatives as Aurora-A kinase inhibitors
    Meenu Beniwal, Neelam Jain, Sandeep Jain, Navidha Aggarwal
    BMC Chemistry, 2022
    IntroductionAurora-A kinase is associated with the Aurora kinase family which has been considered a striking anticancer target for the treatment of human cancers.ObjectiveTo design, synthesize, anticancer evaluation, and docking studies of novel 2-(1-isonicotinoyl-3-phenyl-1H-pyrazol-4-yl)-3-phenylthiazolidin-4-one derivatives as Aurora-A Kinase inhibitors.MethodA total of 21 Pyrazole derivativesP (1–21)were synthesized by using the Vilsmeier Haack reagent which was characterized by FT-IR,1H NMR,13C NMR, and Mass spectroscopy. The synthesized derivatives were evaluated for their potential in vitro anticancer activity by MTT assay and Aurora-A kinase inhibition assay.ResultsThe cytotoxicity assay (MTT assay) showed that compoundP-6exhibited potent cytotoxicity (IC50 = 0.37–0.44 μM) against two cancer (HCT 116 and MCF-7) cell lines, which were comparable to the standard compound, VX-680. CompoundP-6also showed inhibition of Aurora-A kinase with an IC50value of 0.11 ± 0.03 µM. A Docking study was done to compoundP-6andP-20into the active site of Aurora A kinase, in order to get the probable binding model for further study.ConclusionA series of 21 novel pyrazole derivativesP(1–21)were designed, synthesized, in vitro anticancer evaluation, and docking studies for Aurora A kinase inhibition. The results established thatP-6is a prospective aspirant for the development of anticancer agents targeting Aurora-A kinase.
  • Novel Approach for Rapid and Efficient Synthesis of 2-(3-(4-Aryl)-1-isonicotinoyl-4,5-dihydro-1H-pyrazol-4-yl)-3-phenylthiazolidin-4-one Derivatives and Screened Their Antimicrobial Activity
    Meenu Beniwal, Neelam Jain
    Journal of Heterocyclic Chemistry, 2019
    A series of compounds, viz. 2‐(3‐(4‐aryl)‐1‐isonicotinoyl‐4,5‐dihydro‐1H‐pyrazol‐4‐yl)‐3‐phenylthiazolidin‐4‐one 4 (a–n), have been synthesized by reaction of 3 (a–n) with thioglycolic acid in the presence of zinc chloride. Compounds 3 (a–n) have been synthesized by amination of formylated pyrazoles 2 (A–B), which were synthesized by formylation of 1 (A–B) by Vilsmeier–Haack reagent (POCl3/DMF). Compounds 1 (A–B) were synthesized by condensation of hydrazide and substituted acetophenones under conventional method and microwave irradiation method. These compounds were identified on the basis of melting point range, Rf values, infrared, 1H NMR, and mass spectral analysis. These compounds were evaluated for their in vitro antimicrobial activity, and their minimum inhibitory concentration was determined. Among them, compound 4b and compound 4l possess appreciable antimicrobial and antifungal activities. Antibacterial activity results showed that compounds containing electron‐withdrawing groups were more active than compounds containing electron‐releasing groups.
  • Recent Updates on peroxisome proliferator-activated receptor δ agonists for the treatment of metabolic syndrome
    Ajmer S. Grewal, Meenu Beniwal, Deepti Pandita, Bhupinder S. Sekhon, Viney Lather
    Medicinal Chemistry, 2016
    Metabolic syndrome is a disorder described by reduced insulin sensitivity, overweight, hyperlipidaemia, high blood pressure and myocardial disorders, mainly due to high fat diet and lack of physical activity. The peroxisome proliferator activated receptors (PPARs) are type II nuclear hormone receptors that regulate a number of processes in living systems, such as metabolism of carbohydrates and fatty acids, growth and differentiation of cell, and inflammatory reactions. Alpha, gamma and delta are the three distinct isoforms of PPAR. The stimulation of PPARδ alters body's energy fuel preference from glucose to fat. The PPARδ isoform is expressed ubiquitously in all tissues, especially in those tissues which involved in metabolism of lipids like adipose tissue, liver, kidney, and muscle. Currently, PPARδ is an emerging therapeutic target for the pharmacological therapy of disorders associated with metabolic syndrome. Several PPARδ selective agonists had been reported in last ten years, many of them had been advanced into the late phase of clinical trials such as Endurobol (GW501516). However, no PPARδ agonists are yet approved for human use. The present work had been planned to cover wide variety of PPARδ agonists reported till now along with their potential role to tackle various metabolic disorders. The present review has been planned to focus mainly the most popular PPARδ agonists.